argenx SE ARGNF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
argenx Down Nearly 13%, on Pace for Largest Percent Decrease Since December 2023 — Data Talk
-
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
-
argenx SE Up Over 15%, On Pace For Largest Percent Increase Since July 2023 — Data Talk
-
Argenx Shares Rise After Positive Results From Phase 3 Study of Efgartigimod
-
Forte Biosciences Shares Leap Premarket on Takeover by Argenx
-
Argenx to Buy Forte Biosciences for $2.2 Billion
-
FDA Approves Label Expansion For Argenx Treatment of Autoimmune Disease
-
Argenx Shares Fall After Company Drops Trials for Eye-Disease Drug
Trading Information
- Previous Close Price
- $951.43
- Day Range
- $936.00–936.00
- 52-Week Range
- $708.72–1,020.00
- Bid/Ask
- $583.20 / $1,428.52
- Shares Outstanding
- 62.89M
- Market Cap
- $58.21B
- Volume/Avg
- 270 / 171
Key Statistics
- Price/Earnings (Normalized)
- 33.83
- Price/Sales
- 11.71
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,009
- Website
- https://www.argenx.com
Competitors
Valuation
|
Metric
|
ARGNF
|
CSL
|
UCB
|
|---|---|---|---|
Price/Earnings (Normalized) | 33.83 | 20.79 | 16.88 |
Price/Book Value | 6.95 | 4.04 | 3.30 |
Price/Sales | 11.71 | 3.77 | 4.59 |
Price/Cash Flow | 39.12 | 16.87 | 16.09 |
Price/Earnings
ARGNF
CSL
UCB
Financial Strength
|
Metric
|
ARGNF
|
CSL
|
UCB
|
|---|---|---|---|
Quick Ratio | 4.52 | 0.88 | 0.82 |
Current Ratio | 5.12 | 2.21 | 1.20 |
Interest Coverage | 411.30 | −8.46 | 27.73 |
Quick Ratio
ARGNF
CSL
UCB
Profitability
|
Metric
|
ARGNF
|
CSL
|
UCB
|
|---|---|---|---|
Return on Assets (Normalized) | 22.69% | 8.38% | 13.57% |
Return on Equity (Normalized) | 30.35% | 17.61% | 23.59% |
Return on Invested Capital (Normalized) | 24.38% | 11.10% | 19.03% |
Return on Assets
ARGNF
CSL
UCB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|D@l<t? | LOCK|%#X!> | $128B | |||
| Moderna Inc
MRNA
| LOCK|jKdB><H | LOCK|%$ | $79B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|dvF<ww | LOCK|$Q@# | $76B | |||
| argenx SE ADR
ARGX
| LOCK|F%@tvy | LOCK|<c | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|mvMg>Cx | LOCK|p@ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^&GBZ%% | LOCK|CRD# | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Rnb^Ybr | LOCK|@#j>g | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|s!%>Kt | LOCK|$@& | $23B | |||
| Incyte Corp
INCY
| LOCK|#!%sqL | LOCK|y&^ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|MMt#>! | LOCK|SMn | $14B |
United States